Dr. Reddy’s Laboratories is trading at RS 1187.85, up by 1.40 points or 0.12% from its previous close of RS 1186.45 on the BSE.

The stock opened at RS 1181.35 and touched an intraday high of RS 1194.30 and low of RS 1181.35. A total of 2591 shares have been traded so far.

The BSE Group ‘A’ stock with a face value of RS 1 hit a 52-week high of RS 1377.95 on 12-Jun-2025 and a 52-week low of RS 1025.90 on 07-Apr-2025. Over the past week, the stock recorded a high of RS 1218.80 and a low of RS 1176.35. The company’s current market capitalization stands at RS 99437.86 crore.

Shareholding data shows promoters holding 26.64%, while Institutions and Non-Institutions hold 52.67% and 9.86% respectively.

In a business update, Dr. Reddy’s has launched over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market, the generic alternative to Extra Strength Pataday Once-Daily Relief, following approval from the U.S. Food and Drug Administration (USFDA).

The product is an antihistamine eye drop indicated for temporary relief of itchy eyes caused by pollen, ragweed, grass, animal hair, and dander. The Pataday brand recorded approximately USD 69.9 million in U.S. sales during the 52-week period ending December 27, 2025, as per NIQ data. Dr. Reddy’s version is offered in a 2.5 mL bottle.

Dr. Reddy’s Laboratories is a Hyderabad-based multinational pharmaceutical company engaged in manufacturing and marketing a broad portfolio of pharmaceutical products across India and global markets.